# Filing Detail

Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001140361-24-020769
Filing Date
2024-04-19
Accepted
2024-04-19 16:06:05
Documents
6
Period of Report
2024-06-12

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | PRE 14A | ny20022295x1_pre14a.htm | PRE 14A | 577392
2 |  | logo_gyre.jpg | GRAPHIC | 26811
3 |  | ny20022295x1_pc01x1.jpg | GRAPHIC | 603421
4 |  | ny20022295x1_pc02x1.jpg | GRAPHIC | 649812
5 |  | ny20022295x1_pvp01x1.jpg | GRAPHIC | 144669
6 |  | ny20022295x1_pvp02x1.jpg | GRAPHIC | 149456
| Complete submission text file | 0001140361-24-020769.txt |  | 2745368

Mailing Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130
Business Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130 (619) 949-3681
GYRE THERAPEUTICS, INC. (Filer) CIK: 0001124105 (see all company filings)

EIN.: 562020050 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 000-51173 | Film No.: 24857777
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)